Menu
← Oncology Approval Tracker
FDA DECISION ·
Welireg + Keytruda / Keytruda Qlex
belzutifan with pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph · Merck
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adjuvant treatment for adults with clear-cell component renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, with resection of metastatic lesions where applicable.
LAMPGEN ANALYSIS
Why it matters
The HIF-2α inhibitor enters a postsurgical setting with pembrolizumab. Recurrence risk and disease-free survival matter when weighing a combination for patients with no evidence of disease after surgery.
What research teams should watch
Verify pathology, surgery date and risk classification. Track recurrence and distinguish treatment-emergent effects from postsurgical symptoms.
PRIMARY RECORDS